Analysis of the impact of technological changes in the plasma derivative industry on its two main products, normal serum albumin and antihemophilic factor in the United States

1989 1989

Other formats: Order a copy

Abstract (summary)

This study investigated, by written survey, the perceived impact of recent technological changes on the American plasma derivative industry as they affected its two major products, serum albumin and antihemophilic factor (AHF). Those surveyed included product manufacturers, distributors, researchers and end-users.

Survey responses were analyzed to determine which factors were considered most likely to affect the plasma derivative industry, and the degree of consensus or divergence of opinion among and between the various sectors of the industry.

Two factors were viewed as most likely to have an immediate impact on the industry: production of albumin and AHF by genetic engineering, which is nearing reality; and, the realization that despite efforts aimed at viral inactivation, viral infections can be transmitted through transfusion of blood products. Furthermore, there is no industry wide consensus regarding how these changes will affect production, safety, availability, and pricing of plasma products.

Responses indicated that because of the possibility of viral transmission via plasma-derived AHF, there is a perceived need for a genetically engineered substitute for AHF (but not for albumin) and an expectation that such a product will be available soon. Price is viewed as the most important factor for Albumin while safety was the most important factor for AHF. Price was the third most important factor for this product. Respondents generally agreed that higher prices for antihemophilic factor will be accepted if there are improvements in safety, but also in packaging, and distribution systems.

The study concluded that because safety issues were moot with regard to albumin, it and AHF were not viewed as closely similar products although both are derived from human plasma, and each is used in treating serious medical disorders.

Additional changes appear imminent, and the results of the survey reveal that distribution channels for these products are changing. It does seem apparent that the industry will have to develop joint ventures with genetic research companies, and this process is underway. Finally, to remain viable and profitable, manufacturers will have to focus on producing additional products from human plasma.

Indexing (details)

0338: Marketing
0491: Pharmacology
0572: Pharmaceuticals
Identifier / keyword
Health and environmental sciences; Social sciences; Pure sciences; Blood
Analysis of the impact of technological changes in the plasma derivative industry on its two main products, normal serum albumin and antihemophilic factor in the United States
Grossman, Jerrold B.
Number of pages
Publication year
Degree date
School code
DAI-A 50/11, Dissertation Abstracts International
Place of publication
Ann Arbor
Country of publication
United States
Nestor, Oscar
Pace University
University location
United States -- New York
Source type
Dissertations & Theses
Document type
Dissertation/thesis number
ProQuest document ID
Database copyright ProQuest LLC; ProQuest does not claim copyright in the individual underlying works.
Document URL
Access the complete full text

You can get the full text of this document if it is part of your institution's ProQuest subscription.

Try one of the following:

  • Connect to ProQuest through your library network and search for the document from there.
  • Request the document from your library.
  • Go to the ProQuest login page and enter a ProQuest or My Research username / password.